ABSTRACT: Treatment with Intravenous Immunoglobulin (IVIg) 
T reatment with Intravenous Immunoglobulin (IVIg) has been demonstrated to be useful in patients with variety of diseases and Food Drug and Administration has approved the use of IVIg in primary immune defi ciencies, immune thrombocytopenic purpura, kawasaki syndrome, chronic B cell lymphocytic leukemia, CMV infection in transplantation patients and also in pediatric HIV infection. Recently the indications for IVIg have broadened and they are also used in immune mediated disorders like myasthenia gravis, Guillain-Barre syndrome and demyelinating neuropathies. Some IVIg contains sucrose as a stabilizer, which can produce a rare form of nephropathy called Sucrose Nephropathy, which has to be identifi ed and managed quickly. Here we are presenting an interesting case of Sucrose nephropathy.
CASE PRESENTATION
A 62 year old woman with a history for hypertension, diabetes, and stable congestive Heart Failure was hospitalized with petechiae, diagnosed as Acute Idiopathic Th rombocytopenic Purpura. At the time of admission her labs are noted for thrombocytopenia and her renal functions were stable with Blood Urea Nitrogen (BUN) of 24 and Serum Creatinine of 0.8 mgs%. Her urine output is 1800 ml/24 hrs and she was not on any nephrotoxic medications. She was treated with Steroids (Prednisone 60mg/day); during this period her glycemic status was controlled with Insulin. At the end of one week, her platelet counts remained low. Th us one more week of trial with prednisone was continued as she was stable clinically without any bleeding, except for the petechiae in extremities. Despite two weeks of steroid therapy her platelet count was not improving and hence it was decided to start IV Immunoglobulin. She was commenced with IVIg (Sandoglobulin R ) in a dosage of 0.4g/kg/day for a total of 5 consecutive days. Her platelet count improved signifi cantly following the initial 3 doses. However, on day 4, her BUN and Creatinine were raised from the base line. Hence IVIg was stopped. She became oliguric in fi fth day. Her BUN and Creatinine kept on rising (see 4 . When IVIg is administered intravenously sucrase is unavailable to metabolize the sucrose, thus sucrose is delivered unchanged to the kidneys. In human kidneys, the proximal convoluted tubular (PCT) cells are responsible for reabsorption of fi ltered carbohydrates including sucrose, via pinocytosis. After absorption, these pinocytic vesicles coalesce with lysosomes. As the PCT cells cannot hydrolyze sucrose, accumulation of sucrose within the PCT cells results in an increased osmotic gradient, prompting water entry in to the cells via water channels in the apical cell membrane. Th is in turn causes cellular swelling, vacuolization and tubular luminal occlusion from swollen tubular cells. Th is is the proposed underlying pathophysiological mechanism for osmotic nephrosis which clinically manifests as acute renal failure 2 . Th e clinical course of IVIg associated AKI generally follow a similar clinical picture. Acute renal insuffi ciency developing approximately 3 days after the initiation of IVIg and the average duration of renal insuffi ciency is about 13 days 2 . Oliguric renal failure is the predominant feature. AKI was reversible in these situations and usually renal function returned to base line after about 5-10 days of discontinuing the IVIg. Rarely these patients may need renal replacement therapy too.
CONCLUSION
With IVIg infusion, particular caution needs to be exercised in patients with preexisting renal insuffi ciency, diabetes mellitus, elderly (>65 years), volume depletion, sepsis, paraproteinemia 3 Concomitant nephrotoxic drugs should be avoided. Reductions in dose, concentration, and/or rate of administration of IVIg in patients at risk for AKI are the reasonable ways to reduce the risk 4 . Periodic monitoring of renal function tests and urine output is particularly important in patients judged to have a potential risk for developing AKI. At the earliest 
